The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Cardiff Oncology
Stock and Other Ownership Interests - Cardiff Oncology
Travel, Accommodations, Expenses - Cardiff Oncology
A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal Cancer (mCRC).
 
Daniel H. Ahn
Consulting or Advisory Role - Celltrion (I); Eisai; Exelixis; Genentech/Roche
Research Funding - AstraZeneca; Bayer
 
Maya Ridinger
No Relationships to Disclose
 
Mark Erlander
Employment - Cardiff Oncology
Stock and Other Ownership Interests - Cardiff Oncology
Travel, Accommodations, Expenses - Cardiff Oncology
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Bayer (Inst); Celgene (Inst); Immuneering; Imugene; Incyte (Inst); Ipsen (Inst); Lilly (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - ARMO BioSciences; AstraZeneca; Exelixis; Lilly; Merck (Inst); Sillajen
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; GlaxoSmithKline; Isofol Medical; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono